



## King's Research Portal

DOI:

[10.1021/acs.chemrestox.6b00143](https://doi.org/10.1021/acs.chemrestox.6b00143)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Stiborova, M., Indra, R., Moserova, M., Frei, E., Schmeiser, H. H., Kopka, K., Phillips, D. H., & Arlt, V. M. (2016). NADH:Cytochrome b5 reductase and cytochrome b5 can act as sole electron donors to human cytochrome P450 1A1-mediated oxidation and DNA adduct formation by benzo[a]pyrene. *Chemical Research in Toxicology*, 29(8), 1325-1334. <https://doi.org/10.1021/acs.chemrestox.6b00143>

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

**NADH:Cytochrome b<sub>5</sub> Reductase and Cytochrome b<sub>5</sub> Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene**

**Marie Stiborová,<sup>\*,†</sup> Radek Indra,<sup>†</sup> Michaela Moserová,<sup>†</sup> Eva Frei,<sup>†</sup> Heinz H. Schmeiser,<sup>‡</sup> Klaus Kopka,<sup>†</sup> David H. Phillips,<sup>§,⊥</sup> and Volker M. Arlt<sup>§,⊥</sup>**

<sup>†</sup>*Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic*

<sup>‡</sup>*Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany*


<sup>§</sup>*Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment and Health, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom*

<sup>⊥</sup>*NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom*

**Keywords:** cytochrome P450 1A1; NADPH:cytochrome P450 oxidoreductase; NADH:cytochrome b<sub>5</sub> reductase; benzo[a]pyrene; metabolism.

**ABSTRACT:** Benzo[*a*]pyrene (BaP) is a human carcinogen that covalently binds to DNA after activation by cytochrome P450 (P450). Here, we investigated whether NADH:cytochrome *b*<sub>5</sub> reductase (CBR) in the presence of cytochrome *b*<sub>5</sub> can act as sole electron donor to human P450 1A1 during BaP oxidation and replace the canonical NADPH:cytochrome P450 reductase (POR) system. We also studied the efficiencies of coenzymes of these reductases, NADPH as a coenzyme of POR, and NADH as a coenzyme of CBR, to mediate BaP oxidation. Two systems containing human P450 1A1 were utilized: human recombinant P450 1A1 expressed with POR, CBR, epoxide hydrolase and cytochrome *b*<sub>5</sub> in Supersomes™ and human recombinant P450 1A1 reconstituted with POR and/or with CBR and cytochrome *b*<sub>5</sub> in liposomes. BaP-9,10-dihydrodiol, BaP-7,8-dihydrodiol, BaP-1,6-dione, BaP-3,6-dione, BaP-9-ol, BaP-3-ol, a metabolite of unknown structure, and two BaP-DNA adducts were generated by the P450 1A1-Supersomes™ system, both in the presence of NADPH and in the presence of NADH. The major BaP-DNA adduct detected by <sup>32</sup>P-postlabeling was characterized as 10-(deoxyguanosin-*N*<sup>2</sup>-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydro-BaP (assigned adduct 1), while the minor adduct is probably a guanine adduct derived from 9-hydroxy-BaP-4,5-epoxide (assigned adduct 2). BaP-3-ol as the major metabolite, BaP-9-ol, BaP-1,6-dione, BaP-3,6-dione, an unknown metabolite, and adduct 2 were observed in the system using P450 1A1 reconstituted with POR plus NADPH. When P450 1A1 was reconstituted with CBR, and cytochrome *b*<sub>5</sub> plus NADH, BaP-3-ol was the predominant metabolite, too, and an adduct 2 was also generated. Our results demonstrate that the NADH/cytochrome *b*<sub>5</sub>/CBR system can act as the sole electron donor both for the first and second reduction of P450 1A1 during the oxidation of BaP *in vitro*. They suggest that NADH-dependent CBR can replace NADPH-dependent POR in the P450 1A1-catalyzed metabolism of BaP.

## Table of Contents Graphic



## INTRODUCTION

Benzo[*a*]pyrene (BaP) (Figure 1) is a polycyclic aromatic hydrocarbon (PAH) that has been classified as human carcinogen (Group 1) by the International Agency for Research on Cancer.<sup>1</sup> It is a pro-carcinogen requiring metabolic activation catalyzed by cytochrome P450 (P450) enzymes prior to reaction with DNA.<sup>2</sup> Among the P450s, P450 1A1 is the most important enzyme, in combination with microsomal epoxide hydrolase (*mEH*), involved in the metabolic activation of BaP to species forming DNA adducts.<sup>2,3</sup> First, P450 1A1 oxidizes BaP to an epoxide (i.e. BaP-7,8-epoxide) that is then converted to a dihydrodiol by *mEH* (i.e. BaP-7,8-dihydrodiol). Further bioactivation by P450 1A1 leads to the ultimate reactive species, BaP-7,8-dihydrodiol-9,10-epoxide (BPDE) that can react with DNA, forming adducts preferentially at guanine residues (Figure 1). The 10-(deoxyguanosin-*N*<sup>2</sup>-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[*a*]pyrene (dG-*N*<sup>2</sup>-BPDE) adduct is the major product of the reaction of BPDE with DNA *in vitro* and *in vivo*.<sup>4-10</sup> However, BaP is also oxidized to other metabolites such as other dihydrodiols, BaP-diones and further hydroxylated metabolites.<sup>2,6,11-16</sup> Although most of these metabolites are detoxification products, BaP-9-ol is the precursor of 9-hydroxy-BaP-4,5-epoxide that can form another adduct with deoxyguanosine in DNA (Figure 1).<sup>7,8,10,15,17-19</sup>

The P450 enzymes, including P450 1A1, are components of a mixed-function oxidase (MFO) system located in the membrane of endoplasmic reticulum (microsomes). This enzymatic system also contains other enzymes, the multidomain flavoprotein NADPH:cytochrome P450 oxidoreductase (POR) and cytochrome *b*<sub>5</sub> accompanied by its NADH:cytochrome *b*<sub>5</sub> reductase (CBR). Mammalian microsomal P450s function by catalyzing the insertion of one atom of molecular oxygen into a variety of xenobiotics, including BaP, while reducing the other atom to water, a reaction that requires two electrons.<sup>20</sup> The oxygen is activated in the active center of P450s by two electrons. It is

generally accepted that POR with NADPH serves as donor of electrons for both reductions of P450 in the MFO reaction cycle.<sup>20</sup> However, the second electron may also be provided by CBR with cytochrome *b*<sub>5</sub> and NADH, but cytochrome *b*<sub>5</sub> seems to have also additional roles in the monooxygenase system.<sup>20-28</sup>

Although POR is considered an essential constituent of the electron transport chain towards P450,<sup>20</sup> its exact role in the P450-mediated reaction cycle is still not clearly established. Recently we used two mouse models, in which the expression of POR has been permanently (the Hepatic P450 Reductase Null (HRN) line) or conditionally (the Reductase Conditional Null (RCN) line) deleted in hepatocytes leading to a lack of almost all hepatic POR activity. Despite this lack of POR the levels of the P450-mediated dG-*N*<sup>2</sup>-BPDE adducts in the livers of mice of both lines exposed to BaP were higher than in BaP-treated wild-type mice.<sup>7,8,19</sup> These findings suggested BaP activation in other liver cells other than hepatocytes (e.g. Kupffer or endothelial cells),<sup>29</sup> or bioactivation of BaP by non-P450 enzymes (e.g. prostaglandin H synthase and lipoxygenases),<sup>30,31</sup> or combinations of these mechanisms were operative. However, these phenomena might also indicate that another reductase such as microsomal CBR can contribute to the P450-mediated BaP oxidation in these animal models. The latter possibility is supported by experiments with rat P450s indicating the involvement of cytochrome *b*<sub>5</sub> in the NADH-dependent hydroxylation of BaP in a reconstituted P450-containing system.<sup>32,33</sup> Studies using cytochrome *b*<sub>5</sub>-knockout mouse lines, namely, HBN mice (Hepatic cytochrome *b*<sub>5</sub> Null) with a conditional hepatic deletion of cytochrome *b*<sub>5</sub>, and HBRN mice (Hepatic cytochrome *b*<sub>5</sub>/P450 Reductase Null), in which POR and cytochrome *b*<sub>5</sub> are deleted specifically in the liver, also indicate the involvement of CBR in the P450-mediated metabolism of some other P450 substrates.<sup>27,34,35</sup>

We have recently demonstrated that the NADH/cytochrome *b*<sub>5</sub>/CBR system is indeed able to function as the sole electron donor for both reduction steps of rat P450 1A1 during

oxidation of BaP *in vitro*.<sup>15</sup> Although this function of the NADH/cytochrome *b*<sub>5</sub>/CBR system is valid for rat P450 1A1, its role in the reaction cycle catalyzed by the human ortholog of P450 1A1 remained to be explored. To address this question, the present study was carried out, in which we utilized enzymatic systems containing recombinant human P450 1A1 over-expressed in Supersomes™ or pure human recombinant P450 1A1 reconstituted with CBR and cytochrome *b*<sub>5</sub> in liposomes. Results presented here provide evidence that the NADH/cytochrome *b*<sub>5</sub>/CBR system can function as the sole electron donor to human P450 1A1 during BaP oxidation *in vitro*.

## EXPERIMENTAL PROCEDURES

**Cautions:** *BaP is human carcinogen and should be handled with care. Exposure to  $^{32}\text{P}$  should be avoided, by working in a confined laboratory area, with protective clothing, plexiglass shielding, Geiger counters, and body dosimeters. Wastes must be discarded according to appropriate safety procedures.*

**Chemicals and Material.** BaP (CAS no. 50-32-8; purity  $\geq 96\%$ ), NADH (as disodium salt; purity  $\sim 95\%$ ), NADPH (as tetrasodium salt; purity  $\sim 98\%$ ), dilauroyl phosphatidylcholine, glutathione, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), dimethyl sulfoxide (DMSO), 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS) and calf thymus DNA were purchased from Sigma-Aldrich (St. Louis, MO, USA) in ACS purity (purity meets the standards of American Chemical Society), unless stated otherwise. P450 1A1-Supersomes<sup>TM</sup>, microsomes isolated from insect cells transfected with a baculovirus construct containing cDNA of human P450 1A1 and POR that are therefore over-expressed in these microsomes, were purchased from Gentest Corp. (Woburn, MI, USA). However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane [i.e. NADH:cytochrome  $b_5$  reductase (CBR), microsomal EH ( $m\text{EH}$ ) and cytochrome  $b_5$ ] are also expressed at basal levels in these Supersomes<sup>TM</sup> (Gentest Corp., Woburn, MI, USA).

**Preparation of Human Recombinant P450 1A1 and Rat Recombinant POR.** Human recombinant P450 1A1 (EC 1.14.14.1) and rat POR (EC 1.6.2.4) were prepared by heterologous expression in *E. coli* and purified to apparent homogeneity (i.e. as single bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis) as described recently.<sup>36</sup> The specific content of human recombinant CYP1A1 was 11.5 nmol/mg protein. The specific activity of rat recombinant POR measured with cytochrome *c* as a substrate was 49.7  $\mu\text{mol}$



cytochrome *c*/min/mg protein. Both recombinant enzymes were utilized in the reconstitution experiments.<sup>37</sup>

**Isolation of Rat NADH:Cytochrome *b*<sub>5</sub> Reductase and Rabbit Cytochrome *b*<sub>5</sub>.** Cytochrome *b*<sub>5</sub> reductase (CBR) (E.C. 1.6.2.2) was isolated from rat liver microsomes by a procedure described by Perkins and Duncan.<sup>38</sup> The specific activity of rat CBR measured as NADH-ferricyanide reductase was 49.2  $\mu\text{mol}$  ferricyanide/min/mg protein. Cytochrome *b*<sub>5</sub> was isolated from rabbit liver microsomes as described.<sup>39</sup> Both proteins purified to apparent homogeneity<sup>38,39</sup> were utilized in the reconstitution experiments.

**Determination of P450 and Protein Content.** The concentration of P450 was estimated according to Omura and Sato,<sup>40</sup> based on the absorption of the complex of reduced P450 with carbon monoxide. The P450 1A1 content was calculated using an extinction coefficient of 91  $\text{mM}^{-1} \cdot \text{cm}^{-1}$  and estimated to be 11.5 nmol per mg protein. Protein concentrations were determined using a bicinchonic acid assay (BCA; Thermo Fisher Scientific, Waltham, MA, USA) with bovine serum albumin as a standard.<sup>41</sup>

**Reconstitution of Human P450 1A1 with POR or CBR in the Absence and Presence of Cytochrome *b*<sub>5</sub> in Liposomes.** Reconstitution of human P450 1A1 with POR, CBR and/or cytochrome *b*<sub>5</sub> in liposomes was carried out as described previously<sup>19,37</sup> with small modification. Briefly, dilauroyl phosphatidylcholine was dissolved in chloroform (20 mg/ml) and a lipid film was obtained by evaporation of chloroform by a stream of nitrogen. The lipid film was dispersed with 50 mM HEPES/KOH buffer, pH 7.4, containing 3 mM reduced glutathione, 0.1  $\mu\text{M}$  CHAPS and sonicated twice at 20°C for 3 min. The appropriate amounts of human recombinant P450 1A1 and rat recombinant POR or human recombinant P450 1A1 and purified rat CBR (200 pmol in a ratio of 1:1), without or with cytochrome *b*<sub>5</sub> (in a ratio of P450 1A1 with reductase to cytochrome *b*<sub>5</sub> of 1:5) were added to the prepared dispersion and incubated at 20°C for 10 min. As shown in previous studies,<sup>19,25,37,42,43</sup> the enzymatic activity

of human P450 1A1 reconstituted with POR and cytochrome *b*<sub>5</sub> from several animal models was the same as that of the enzyme reconstituted with the human orthologs of these enzymes.

**Incubations to Study the Metabolism of BaP by Human Recombinant P450 1A1 in Supersomes™ or by Human Recombinant P450 1A1 Reconstituted with POR or CBR in the Presence or Absence of Cytochrome *b*<sub>5</sub> in Liposomes.** Incubation mixtures used to study BaP metabolism by human recombinant P450 1A1 in the presence of other components of the MFO-systems in Supersomes™ contained 100 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH or NADH, 50 μM BaP (dissolved in 5 μl DMSO) and 100 nM human recombinant P450 1A1 in a final volume of 0.5 ml. The same amount of a solvent (DMSO) was used in control incubations without BaP. With this DMSO concentration (1 % as a final concentration) no inhibition of the NADPH-dependent P450-catalyzed oxidation of several substrates has been found previously.<sup>7,8,19,25,28,44</sup> The reaction was initiated by adding the NADPH or NADH.

In separate experiments 100 nM pure human recombinant P450 1A1 reconstituted individually with other components of the MFO-system was used instead of P450 1A1 in Supersomes™. Negative control reactions lacked either P450 1A1, reductases or BaP. After incubation (37°C, 20 min), 5 μl of 1 mM phenacetin in methanol was added as an internal standard. BaP metabolism by the P450 1A1 systems has been shown to be linear up to 30 min of incubation.<sup>15,16,19</sup> BaP metabolites were extracted twice with ethyl acetate (2 × 1 ml), the solvent was evaporated to dryness, the residues were dissolved in 25 μl methanol and subsequently BaP metabolites were separated by HPLC as reported.<sup>19,45</sup> BaP metabolite peaks were analyzed by HPLC by comparison with metabolite standards whose structures were determined previously by NMR and/or mass spectrometry.<sup>19</sup>

**Determination of BaP-DNA Adduct Formation by <sup>32</sup>P-postlabeling.** Incubation mixtures used to assess DNA adduct formation by BaP activated with all enzymatic systems

containing human P450 1A1 consisted of 50 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH or NADH, 100 nM human recombinant P450 1A1 plus other enzymes as indicated in the figures (or as described above), 0.1 mM BaP (dissolved in 7.5  $\mu$ l DMSO), and 0.5 mg of calf thymus DNA in a final volume of 0.75 ml as described previously.<sup>19</sup> The reaction was initiated by adding 0.1 mM BaP and incubations were carried out at 37°C for 60 min. BaP-DNA adduct formation has been shown to be linear up to 90 min.<sup>7,19</sup> Control incubations were carried out without P450 1A1, or without reductases, or without cytochrome *b*<sub>5</sub>, or without NADPH (or NADH), or without DNA, or without BaP. After the incubation, DNA was isolated from the residual water phase by standard phenol/chloroform extraction. DNA adduct formation was analyzed using the nuclease P1 version of the <sup>32</sup>P-postlabeling technique.<sup>7,19</sup> Resolution of the adducts by thin-layer chromatography (TLC) using polyethylenimine-cellulose plates (Macherey and Nagel, Düren, Germany) was carried out as described.<sup>7,19,46</sup> DNA adduct levels (RAL, relative adduct labelling) were calculated as described.<sup>47</sup>

**Statistical Analyses.** Statistical analyses were carried out on the means  $\pm$  standard deviations of three parallel experiments with Student's *t*-test (UNISTAT Statistics Software v6, Unistat Ltd., Highgate, London N6 5UQ, UK) and *p* < 0.05 was considered significant. Statistical association between amounts of BaP metabolites formed by oxidation of BaP by the P450 reconstituted systems containing POR or CBR and levels of BaP-DNA adduct 2 formed by the same systems were determined by the Spearman correlation coefficients using version 6.12 Statistical Analysis System software. Spearman correlation coefficients were based on a sample size of 6. All *P*s are two-tailed and considered significant at the 0.05 level.

## RESULTS

**Oxidation of BaP by Human P450 1A1 Expressed in Supersomes™ and Pure Human Recombinant P450 1A1 Reconstituted with POR or CBR.** In order to evaluate the role of POR and CBR in the reduction of human P450 1A1 during BaP oxidation, two enzymatic systems containing this human P450 were utilized. The first system used Supersomes™ containing human recombinant P450 1A1 expressed with POR, CBR, *mEH* and/or cytochrome *b<sub>5</sub>*. In the second system, pure human recombinant P450 1A1 was reconstituted in liposomes with either pure POR or CBR. The latter enzymatic system was utilized with or without cytochrome *b<sub>5</sub>* to examine the function of both reductases as electron donors to P450 1A1 during BaP metabolism with NADPH (cofactor of POR) or NADH (cofactor of CBR). The BaP metabolites formed by human P450 1A1 in these enzyme systems were analyzed by HPLC (Figure 2A).

Seven BaP metabolites were formed in Supersomes™ containing human P450 1A1, both in the presence of NADPH and NADH (Figure 2). They were structurally characterized previously<sup>16,19</sup> as BaP-9,10-dihydrodiol (M1), BaP-7,8-dihydrodiol (M3), BaP-1,6-dione (M4), BaP-3,6-dione (M5), BaP-9-ol (M6) and BaP-3-ol (M7). The structures of these BaP metabolites are shown in Figure 2B. In addition, a metabolite of unknown structure (Mx) was detected. Essentially no BaP metabolites were found when both NADPH and NADH were omitted from the incubation mixtures containing the P450 1A1-Supersomes™ (Figure 2C). NADH was less effective than NADPH to act as electron donor to human P450 1A1 in Supersomes™ (Figure 2C). Addition of cytochrome *b<sub>5</sub>* to the incubation mixtures led to an increase in P450 1A1-mediated BaP oxidation both in the presence of NADPH and in the presence of NADH (Figure 2C).

In the second enzymatic system, where pure human recombinant P450 1A1 was reconstituted with POR with or without cytochrome *b<sub>5</sub>* in liposomes, this P450 enzyme was

also able to oxidize BaP in the presence of NADPH (Figure 3). Only five BaP metabolites were formed, which were BaP-3-ol (M7) as the major metabolite, BaP-9-ol (M6), BaP-1,6-dione (M4), BaP-3,6-dione (M5) and metabolite Mx (Figure S1). Because *mEH* was absent from the system, no dihydrodiols were formed. Addition of cytochrome *b*<sub>5</sub> to this P450 1A1 system increased formation of all BaP metabolites, in particular BaP-3-ol (Figure 3 and Figure S1). In contrast, NADH did not lead to significant BaP oxidation by P450 1A1 reconstituted with POR (Figure 3 and Figure S1), which confirms that NADH functions as a coenzyme of POR at very slow rate that is negligible relative to NADPH, as we showed recently with cytochrome *c* as a substrate for POR.<sup>15</sup> No BaP metabolites were found when both NADPH and NADH were omitted from the incubation mixtures containing the human recombinant P450 1A1 reconstituted with POR or CBR (Figure 3).

In the enzymatic system where human P450 1A1 was reconstituted with CBR and cytochrome *b*<sub>5</sub> in liposomes, BaP was predominantly oxidized to BaP-3-ol (M7) and to a lower extent to BaP-9-ol (M6), BaP-1,6-dione (M4), BaP-3,6-dione (M5) and a metabolite Mx (Figure S1). Cytochrome *b*<sub>5</sub> as a substrate of CBR was necessary for BaP oxidation in the system of human P450 1A1 reconstituted with CBR with NADH as cofactor. Without this protein, essentially no BaP oxidation was detectable by P450 1A1 reconstituted with CBR (Figure 3 and Figure S1). Addition of POR to the reconstituted system of human P450 1A1 with CBR and cytochrome *b*<sub>5</sub> did not change BaP metabolite levels (Figure 3 and Figure S1).

**Formation of BaP-DNA adducts by human P450 1A1 expressed in Supersomes™ and by human P450 1A1 reconstituted with POR or CBR.** In further experiments, the formation of DNA adducts by BaP incubated with human P450 1A1 expressed in Supersomes™ and human P450 1A1 reconstituted with POR or CBR was analyzed. First, we utilized human recombinant P450 1A1 expressed in Supersomes™ with other enzyme components of the microsomal monooxygenase system. Up to two DNA adducts (assigned

adducts 1 and 2; see insert in Figure 1) were detected by  $^{32}\text{P}$ -postlabeling in incubations where BaP was activated with human P450 1A1 in Supersomes<sup>TM</sup>, in the presence of either NADPH or NADH. No such BaP adducts were found when both NADPH and NADH were omitted from the incubation mixtures containing the P450 1A1-Supersomes<sup>TM</sup> (Figure 4). Adduct 1 was the BaP-DNA adduct predominantly formed in this system (Figure 4). Comparison with previous  $^{32}\text{P}$ -postlabeling analyses<sup>10,19</sup> showed that adduct 1 is the dG- $N^2$ -BPDE adduct.<sup>10,19</sup> The other adduct, which was formed in this enzymatic system as only a minor product, if detectable at all (e.g. there was no formation of this adduct in Supersomes<sup>TM</sup> in the presence of NADPH), has similar chromatographic properties by TLC to a guanine adduct derived from reaction with 9-hydroxy-BaP-4,5-epoxide (see adduct spot 2 in insert of Figure 1 and Figure 5A). Addition of cytochrome  $b_5$  to P450 1A1 in Supersomes<sup>TM</sup>, increased the levels of the dG- $N^2$ -BPDE adduct generated by human P450 1A1 in the presence of NADH (Figure 4), similar to the increase observed in BaP oxidation (Figure 2).

Pure human recombinant P450 1A1 reconstituted with POR in the presence of NADPH formed only adduct 2 (Figures 5B and 6). Because of the absence of  $mEH$ , no adduct 1 (i.e. dG- $N^2$ -BPDE) was formed. Addition of cytochrome  $b_5$  to this P450 1A1 system decreased the levels of adduct 2, but this decrease was not statistically significant (Figure 6). NADH was essentially ineffective to mediate the activation of BaP by P450 1A1 reconstituted with POR (Figures 5B and 6), which again indicates that NADH functions as a coenzyme of POR at very slow rate that is negligible relative to NADPH.

Human P450 1A1 reconstituted with CBR and cytochrome  $b_5$  also generated adduct 2. The presence of cytochrome  $b_5$  as a substrate of CBR and NADH as its cofactor was essential for this adduct formation; NADPH, the cofactor of POR, was ineffective (Figures 5B and 6). No BaP-DNA adduct 2 was found when both NADPH and NADH were omitted from the incubation mixtures containing human recombinant P450 1A1 reconstituted with POR or

CBR (Figure 6). Levels of adduct 2 formed by human P450 1A1 in the presence of the NADH/cytochrome *b<sub>5</sub>*/CBR system were lower than those formed in the system of human P450 1A1 containing POR and NADPH (Figures 5 and 6). These results corresponded to lower levels of BaP-9-ol (a precursor of 9-hydroxy-BaP 4,5-epoxide generating this adduct) and other BaP metabolites formed in this system (see Figure S1). Significant correlations were found between levels of adduct 2 and BaP-9-ol ( $r = 0.943$ ,  $P < 0.001$ , Spearman's correlations) or BaP-3-ol ( $r = 0.943$ ,  $P < 0.001$ ), whereas no such correlations were found between levels of this adduct and BaP-1,6-dione, BaP-3,6-dione or a metabolite Mx ( $r < 0.5$ ).

## DISCUSSION

The metabolism of BaP has been extensively studied over the past decades<sup>2</sup> and various studies have examined the role of P450 enzymes, particularly P450 1A1 of several species, to metabolize this carcinogen.<sup>2,6,7,8,15,16,19,28,44</sup> However, the mechanism of the reaction cycle of BaP oxidation catalyzed by P450 1A1, particularly the roles of POR and CBR as electron donors to P450 1A1, has not yet been fully resolved.<sup>7,8,15,19</sup> Enigmatic results have been found in two mouse models where deletion of POR in hepatocytes did not lead to an expected decrease in BaP-DNA adduct formation in liver *in vivo*, but instead to higher BaP-DNA binding.<sup>7,8,19</sup> We also showed that in livers of HRN mice P450 1A1, cytochrome *b*<sub>5</sub> and *mEH* can effectively activate BaP to DNA binding species, even in the presence of very low amounts of POR.<sup>19</sup> Because this feature has biological significance, studying the role of the enzymes reducing P450 1A1 is important to better understand the mechanism(s) involved in BaP metabolism. Recently we demonstrated that the NADH/cytochrome *b*<sub>5</sub>/CBR system is able to function as the sole donor of electrons for both reduction steps of rat P450 1A1 during BaP oxidation *in vitro*.<sup>15</sup> This finding indicates that CBR as an NADH-dependent reductase might substitute POR in the P450 1A1-mediated BaP metabolism and might help to explain our enigmatic results in the POR-knockout mouse models.<sup>7,8,19</sup> However, the question whether this novel function of the NADH/cytochrome *b*<sub>5</sub>/CBR system as electron donor to rat P450 1A1 in BaP metabolism represents a general feature for the P450 1A1 reaction cycle in other species including humans remained to be answered. Therefore, the primary aim of this study was to determine whether the NADH/cytochrome *b*<sub>5</sub>/CBR system can be the exclusive donor of both electrons to the P450 1A1 human orthologue during BaP metabolism *in vitro*. To this end two enzymatic systems containing this human P450 were utilized: (1) microsomes of baculovirus-infected insect cells (Supersomes™) containing human recombinant P450 1A1 expressed with POR, CBR, *mEH* and cytochrome *b*<sub>5</sub> and (2) pure human P450 1A1



heterologously expressed in *E. coli* reconstituted either with pure POR or CBR with cytochrome *b*<sub>5</sub> in liposomes.

Using the first system, human P450 1A1-Supersomes™, we proved that NADH acts as electron donor for both reductions of the P450 1A1 human orthologue in BaP oxidation independent of NADPH and POR if CBR and cytochrome *b*<sub>5</sub> is present. This conclusion is supported by the fact that NADH functions as a poor coenzyme of POR when cytochrome *c* is used as its substrate.<sup>15</sup> Our results therefore confirm the novel feature on the mechanism of the catalytic cycle of human P450 1A1 during BaP oxidation previously described for rat P450 1A1. We demonstrated that the reaction cycle of BaP oxidation catalyzed by human P450 1A1 can proceed by ways that differ from the generally accepted mechanism, where the first reduction of P450 is considered to be catalyzed by POR without cytochrome *b*<sub>5</sub>.<sup>20,48-52</sup> Considering the redox potentials of cytochrome *b*<sub>5</sub> (+20 mV)<sup>53,54</sup> and ferric substrate-bound P450 (−237 mV)<sup>27,53</sup> it is thermodynamically impossible for cytochrome *b*<sub>5</sub> to provide the first electron in the P450 catalytic cycle<sup>55</sup>. Given that the redox potential of oxyferrous P450 is also approximately +20 mV, it is feasible that cytochrome *b*<sub>5</sub> can supply the second electron into the catalytic cycle.<sup>27,53,55</sup> However, based on the redox potential of CBR determined under the anaerobic conditions (−265 mV)<sup>56</sup> it could provide the first electron in the P450 catalytic cycle.<sup>27,57</sup> Moreover, considering the effect of Le Chatelier's principle given, the reduced P450 will rapidly bind dioxygen under aerobic conditions of the experiments. Indeed, in the present study we demonstrate that the first reduction of P450 1A1 which previously had been considered to be mediated exclusively by the NADPH/POR system can be substituted by the NADH/cytochrome *b*<sub>5</sub>/CBR system. This reaction was found not only in Supersomes™ containing human recombinant P450 1A1, but, even more importantly, in the system of pure human P450 1A1 reconstituted with CBR and cytochrome *b*<sub>5</sub>. Such NADH/cytochrome *b*<sub>5</sub>/CBR-mediated activity of the human P450 1A1 systems was proven by the formation of up

to seven BaP metabolites [BaP-9,10-dihydrodiol (M1), BaP-7,8-dihydrodiol (M3), BaP-1,6-dione (M4), BaP-3,6-dione (M5), BaP-9-ol (M6), BaP-3-ol (M7) and a metabolite of unknown structure (Mx)]. In addition, these systems generated two BaP-DNA adducts, the dG- $N^2$ -BPDE adduct (adduct 1) and/or a guanine adduct derived from the reaction with 9-hydroxy-BaP-4,5-epoxide (adduct 2). The BaP metabolite profiles formed by P450 1A1 with the NADH/cytochrome  $b_5$ /CBR system were the same as in the system where NADPH and POR were used as electron donors. BaP-4,5-dihydrodiol (M2), which was previously found to be formed by rat P450 1A1<sup>15,19</sup> was not generated by the human P450 1A1 orthologue (Figure 2). This finding is in line with previous findings showing that this BaP metabolite was not formed in human bronchoalveolar H358 cells expressing P450 1A1 after BaP exposure.<sup>13</sup>

Interestingly, essentially no differences in the levels of dG- $N^2$ -BPDE adducts were seen when using either NADPH or NADH as cofactors in the P450 1A1-Supersomes™ system (see Figure 4). However, it should be noted that the oxidation reaction of BaP to its metabolites was catalyzed less efficiently by NADH than by NADPH in this system (see Figure 2). One reason might be the effects of the different experimental conditions used for the incubations utilized for BaP metabolite analysis and BaP-DNA adduct formation (*i.e.* incubation times, concentrations of BaP, the presence or absence of DNA, see the Experimental Procedures section).

In summary, this study demonstrates for the first time that NADH, CBR and cytochrome  $b_5$  can act as sole electron donors for both the first and second reduction of human P450 1A1 during the oxidative metabolism of BaP and formation of BaP-DNA adducts *in vitro*. These findings confirm our results of a recent study where rat P450 1A1 was utilized to study BaP metabolism.<sup>15</sup> However, although the role of the NADH/cytochrome  $b_5$ /CBR system in both reductions of rat<sup>15</sup> and human P450 1A1<sup>present work</sup> is proven in our *in vitro* studies, further investigations are needed in the future. In this context, the mechanism of both the first and

second reduction of P450 1A1 remains to be examined in detail. In addition, as shown by Guengerich and coworkers for the P450 3A4-mediated 6-hydroxylation of testosterone<sup>57</sup>, the question whether NADH/cytochrome *b*<sub>5</sub>/CBR system might also reduce other P450 enzymes needs to be addressed. This might be the case in rat hepatic microsomes where various P450s were induced by their specific inducers; in these microsomes, BaP was oxidized not only in the presence of NADPH, but also in the presence of NADH.<sup>15</sup> Another crucial question that remains to be addressed relates to the impact of the NADH/cytochrome *b*<sub>5</sub>/CBR system on BaP metabolism *in vivo*. Recent *in vivo* experiments using cytochrome *b*<sub>5</sub>-knockout mouse lines (*i.e.* HBN and HBRN) provide evidence that in the absence of POR, cytochrome *b*<sub>5</sub>/CBR are capable of supplying electrons for P450 catalytic function (*i.e.* in metabolism of the P450 3A substrate midazolam).<sup>27</sup> It is anticipated that these mouse lines will help to elucidate the different mechanisms of P450-catalyzed BaP biotransformation *in vivo*.

## **AUTHOR INFORMATION**

### **Corresponding Author**

\*Phone: +420 221951285; Fax: +420 221951283. E-mail: [stiborov@natur.cuni.cz](mailto:stiborov@natur.cuni.cz)

### **Funding**

Supported by GACR (grant 14-18344S in panel P301) and Charles University (grant UNCE 204025/2012). Work at King's College London is supported by Cancer Research UK (grant number C313/A14329), the Wellcome Trust (Grants 101126/Z/13/Z and 101126/B/13/Z), the Natural Environmental Research Council (NE/L006782/1) and in part by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England (PHE).

### **Notes**

The authors declare no competing financial interest.

## ABBREVIATIONS

BaP, benzo[*a*]pyrene; BPDE, BaP-7,8-dihydrodiol-9,10-oxide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate; CBR, NADH:cytochrome *b*<sub>5</sub> reductase; P450, cytochrome P450; dG-*N*<sup>2</sup>-BPDE, 10-(deoxyguanosin-*N*<sup>2</sup>-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[*a*]pyrene; DMSO, dimethyl sulfoxide; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HBN, Hepatic cytochrome *b*<sub>5</sub> Null; HPLC, high performance liquid chromatography; HBRN, Hepatic cytochrome *b*<sub>5</sub>/P450 Reductase Null; HRN; Hepatic P450 Reductase Null; *m*EH, microsomal epoxide hydrolase; MFO, mixed-function oxidase; POR, NADPH:P450 oxidoreductase; RAL, relative adduct labeling; RCN, Reductase Conditional Null; TLC, thin-layer chromatography.

## Description of the Supporting Information material

This material is available free of charge via the Internet at <http://pubs.acs.org>.

## REFERENCES

- (1) IARC (International Agency for Research on Cancer) (2010) Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. In *IARC Monogr. Eval. Carcinog. Risks Hum.* Vol. 92, IARC, Lyon, France, pp. 1-853.
- (2) Baird, W.M., Hooven, L.A., and Mahadevan, B. (2005) Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. *Environ. Mol. Mutagen.* 45, 106-114.
- (3) Wohak, L.E., Kraus, A.M., Kucab, J.E., Stertmann, J., Øvrebø, S., Seidel, A., Phillips, D.H., and Arlt, V.M. (2016) Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells *via* a p53-dependent mechanism. *Arch. Toxicol.* 90, 291-304.
- (4) Sims, P., Grover, P.L., Swaisland, A., Pal, K., and Hewer, A. (1974). Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. *Nature* 252, 326-328.
- (5) Wood, A.W., Levin, W., Lu, A.Y., Yagi, H., Hernandez, O., Jerina, D.M., and Conney, A.H. (1976) Metabolism of benzo(a)pyrene and benzo(a)pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. *J. Biol. Chem.* 251, 4882-4890.
- (6) Bauer, E., Guo, Z., Ueng, Y.F., Bell, L.C., Zeldin, D., and Guengerich, F.P. (1995) Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes. *Chem. Res. Toxicol.* 8, 136-142.
- (7) Arlt, V.M., Stiborova, M., Henderson, C.J., Thiemann, M., Frei, E., Aimova, D., Singhs, R., Costa, da G.G., Schmitz, O.J., Farmer, P.D., Wolf, C.R., and Phillips, D.H. (2008) Metabolic activation of benzo[a]pyrene *in vitro* by hepatic cytochrome P450 contrasts with detoxification *in vivo*: experiments with hepatic cytochrome P450 reductase null mice. *Carcinogenesis* 29, 656-665.
- (8) Arlt, V.M., Poirier, M.C., Sykes, S.E., John, K., Moserova, M., Stiborova, M., Wolf, C.R., Henderson, C.J., and Phillips, D.H. (2012) Exposure to benzo[a]pyrene of Hepatic

- Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and  $^{32}\text{P}$ -postlabelling. *Toxicol. Lett.* 213, 160-166.
- (9) Arlt, V.M., Krais, A.M., Godschalk, R.W., Rizzo-Vasquez, Y., Mrizova, I., Roufosse, C.A., Corbin, C., Shi, Q., Frei, E., Stiborova, M., van Schooten, F.J., Phillips, D.H., and Spina, D. (2015) Pulmonary inflammation impacts on CYP1A1-mediated respiratory tract DNA damage induced by the carcinogenic air pollutant benzo[a]pyrene. *Toxicol. Sci.* 146, 213-225.
- (10) Krais, A.M., Speksnijder, E.N., Melis, J.P., Indra, R., Moserova, M., Godschalk, R.W., van Schooten, F.J., Seidel, A., Kopka, K., Schmeiser, H.H., Stiborova, M., Phillips, D.H., Luijten, M., and Arlt, V.M. (2016). The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice. *Arch. Toxicol.* 90, 291-304.
- (11) Chun, Y.J., Shimada, T., and Guengerich, F.P. (1996) Construction of a human cytochrome P450 1A1: rat NADPH-cytochrome P450 reductase fusion protein cDNA and expression in *Escherichia coli*, purification, and catalytic properties of the enzyme in bacterial cells and after purification. *Arch. Biochem. Biophys.* 330, 48-58.
- (12) Kim, J.H., Stansbury, K.H., Walker, N.J., Trush, M.A., Strickland, P.T., and Sutter, T.R. (1998) Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. *Carcinogenesis* 19, 1847-1853.
- (13) Jiang, H., Gelhaus, S.L., Mangal, D., Harvey, R.G., Blair, I.A., and Penning, T.M. (2007) Metabolism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid chromatography-mass spectrometry. *Chem. Res. Toxicol.* 20, 1331-1341.
- (14) Zhu, S., Li, L., Thornton, C., Carvalho, P., Avery, B.A., and Willett, K.L. (2008) Simultaneous determination of benzo[a]pyrene and eight of its metabolites in *Fundulus*

- heteroclitus bile using ultra-performance liquid chromatography with mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 863, 141-149.
- (15) Stiborová, M., Indra, R., Moserová, M., Šulc, M., Hodek, P., Frei, E., Schmeiser, H.H., and Arlt, V.M. (2016) NADPH- and NADH-dependent metabolism of and DNA adduct formation by benzo[a]pyrene catalyzed with rat hepatic microsomes and cytochrome P450 1A1. *Monatsh. Chem.* 147, 847-855.
- (16) Šulc, M., Indra, R., Moserová, M., Schmeiser, H.H., Frei, E., Arlt, V.M., and Stiborová, M. (2016) The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers. *Environ. Mol. Mutagen.* 57, 229-235
- (17) King, H.W., Thompson, M.H., and Brookes, P. (1976) The role of 9-hydroxybenzo(a)pyrene in the microsome mediated binding of benzo(a)pyrene to DNA. *Int. J. Cancer* 18, 339-344.
- (18) Fang, A.H., Smith, W.A., Vouros, P., Gupta, R.C. (2001) Identification and characterization of a novel benzo[a]pyrene-derived DNA adduct. *Biochem. Biophys. Res. Commun.* 281, 383-389.
- (19) Stiborova, M., Moserova, M., Cerna, V., Indra, R., Dracinsky, M., Šulc, M., Henderson, C.J., Wolf, C.R., Schmeiser, H.H., Phillips, D.H., Frei, E., and Arlt, V.M. (2014) Cytochrome *b*<sub>5</sub> and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. *Toxicology* 318, 1-12.
- (20) Guengerich, F.P. (2008) Cytochrome P450 and chemical toxicology. *Chem. Res. Toxicol.* 21, 70-83.
- (21) Porter, T.D. (2002) The roles of cytochrome *b*<sub>5</sub> in cytochrome P450 reactions. *J. Biochem. Mol. Toxicol.* 16, 311-316.

- (22) Schenkman, J.B., and Jansson, I. (2003) The many roles of cytochrome *b*<sub>5</sub>. *Pharmacol. Ther.* 97, 139-152.
- (23) Guengerich, F.P. (2005) Reduction of cytochrome *b*<sub>5</sub> by NADPH-cytochrome P450 reductase. *Arch. Biochem. Biophys.* 440, 204-211.
- (24) McLaughlin, L.A., Ronseaux, S., Finn, R.D., Henderson, C.J., and Wolf, C.R. (2010) Deletion of microsomal cytochrome *b*<sub>5</sub> profoundly affects hepatic and extrahepatic drug metabolism. *Mol. Pharmacol.* 75, 269-278.
- (25) Kotrbova, V., Mrazova, M., Moserova, M., Martinek, V., Hodek, P., Hudecek, J., Frei, E., and Stiborova, M. (2011) Cytochrome *b*<sub>5</sub> shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy. *Biochem. Pharmacol.* 82, 669-680.
- (26) Stiborova, M., Indra, R., Moserova, M., Cerná, V., Rupertová, M., Martínek, V., Eckschlager, T., Kizek, R., and Frei, E. (2012) Cytochrome *b*<sub>5</sub> increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and *N,O*-acetyltransferases. *Chem. Res. Toxicol.* 25, 1075–85.
- (27) Henderson, C.J., McLaughlin, L.A., and Wolf, C.R. (2013) Evidence that cytochrome *b*<sub>5</sub> and cytochrome *b*<sub>5</sub> reductase can act as sole electron donors to the hepatic cytochrome P450 system. *Mol. Pharmacol.* 83, 1209-1217.
- (28) Indra, R., Moserova, M., Sulc, M., Frei, E., and Stiborova, M. (2013) Oxidation of carcinogenic benzo[a]pyrene by human and rat cytochrome P450 1A1 and its influencing by cytochrome *b*<sub>5</sub> – a comparative study. *Neuro Endocrinol. Lett.*, 34 (Suppl 2), 55-63.
- (29) Steinberg, P., Schlemper, B., Molitor, E., Platt, K.L., Seidel, A., and Oesch, F. (1990) Rat liver endothelial and Kupffer cell-mediated mutagenicity of polycyclic aromatic hydrocarbons and aflatoxin B1. *Environ. Health Perspect.* 88, 71-76.



- (30) Marnett, L.J., and Bienkowski, M.J. (1980) Hydroperoxide-dependent oxygenation of trans-7,8-dihydroxy-7,8-dihydro benzo[a]pyrene by ram seminal vesicle microsomes, Source of the oxygen. *Biochem. Biophys. Res. Commun.* 96, 639-647.
- (31) Marnett, L.J. (1990) Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxy radicals as reactive intermediates. *Environ. Health Perspect.* 88, 5-12.
- (32) West, S.B., Levin, W., Ryan, D., Vore, M., and Lu, A.Y. (1974) Liver microsomal electron transport systems. II. The involvement of cytochrome *b*<sub>5</sub> in the NADH-dependent hydroxylation of 3,4-benzpyrene by a reconstituted cytochrome P-448-containing system. *Biochem. Biophys. Res. Commun.* 58, 516-522.
- (33) Lu, A.Y., West, S.B., Vore, M., Ryan, D., Levin, W. (1974) Role of cytochrome *b*<sub>5</sub> in hydroxylation by a reconstituted cytochrome P-450-containing system. *J. Biol. Chem.* 249, 6701-6709.
- (34) Finn, R.D., McLaughlin, L.A., Ronseaux, S., Rosewell, I., Houston, J.B., Henderson, C.J., Wolf, C.R. (2008) Defining the *in vivo* role for cytochrome *b*<sub>5</sub> in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome *b*<sub>5</sub>. *J. Biol. Chem.* 283, 31385-31393.
- (35) Henderson, C.J., McLaughlin, L.A., Scheer, N., Stanley, L.A., and Wolf, C.R. (2015) Cytochrome *b*<sub>5</sub> is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity *in vivo*. *Mol. Pharmacol.* 87, 733-739.
- (36) Milichovský, J., Bárta, F., Schmeiser, H.H., Arlt, V.M., Frei, E., Stiborová, M. and Martínek, V. (2016) Active site mutations as a suitable tool contributing to explain a mechanism of aristolochic acid I nitroreduction by cytochromes P450 1A1, 1A2 and 1B1. *Int. J. Mol. Sci.* 17, pii: E213.

- (37) Stiborová, M., Martínek, V., Rýdlová, H., Hodek, P., and Frei, E. (2002) Sudan I is a potential carcinogen for humans: Evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. *Cancer Res.* 62, 5678-5684.
- (38) Perkins, D.M., and Duncan, J.R. (1987) Improved isolation of rat microsomal cytochrome *b*<sub>5</sub> reductase. *J. Chromatogr.* 405, 319-325.
- (39) Ross, P.H. (1996) Chromatographic separation and behavior of microsomal cytochrome P450 and cytochrome *b*<sub>5</sub>. *J. Chromatogr. B* 684, 107-131.
- (40) Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes: I Evidence for its hemoprotein nature. *J. Biol. Chem.* 239, 2370–2378.
- (41) Wiechelman, K.J., Braun, R.D., and Fitzpatrick, J.D. (1988) Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation. *Anal. Biochem.* 175, 231–237.
- (42) Stiborová, M., Sejbál, J., Bořek-Dohalská, L., Aimová, D., Poljaková, J., Forsterová, K., Rupertová, M., Wiesner, J., Hudeček, J., Wiessler, M., and Frei, E. (2004) The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine *N*<sup>2</sup>-oxide. *Cancer Res.* 64, 8374-8380.
- (43) Kotrbová, V., Aimová, D., Březinová, A., Janouchová, K., Poljaková, J., Hodek, P., Frei, E., and Stiborová, M. (2006) Cytochromes P450 reconstituted with NADPH:P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes. *Neuro Endocrinol. Lett.* 27 (Suppl. 2), 18-20.
- (44) Indra, R., Moserová, M., Kroftová, N., Sulc, M., Martinková, M., Adam, V., Eckschlager, T., Kizek, R., Arlt, V.M., and Stiborová, M. (2014) Modulation of human

- cytochrome P450 1A1-mediated oxidation of benzo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and cytochrome *b*<sub>5</sub>. *Neuro Endocrinol. Lett.* 35 (Suppl 2),105-113.
- (45) Moserová, M., Kotrbová, V., Aimová, D., Šulc, M., Frei, E., Stiborová, M. (2009) Analysis of benzo[a]pyrene metabolites formed by rat hepatic microsomes using high pressure liquid chromatography: optimization of the method. *Interdisc. Toxicol.* 2, 239-244.
- (46) Hodek, P., Koblihová, J., Kizek, R., Frei, E., Arlt, V.M., and Stiborová, M. (2013) The relationship between DNA adduct formation by benzo[a]pyrene and expression of its activation enzyme cytochrome P450 1A1 in rat. *Environ. Toxicol. Pharmacol.* 36, 989-996.
- (47) Schmeiser, H.H., Stiborova, M., and Arlt, V.M. (2013) <sup>32</sup>P-postlabeling analysis of DNA adducts. *Methods Mol. Biol.* 1044, 389–401.
- (48) Sligar, S.G., Cinti, D.L., Gibson, G.G., Schenkman, J.B. (1979) Spin state control of the hepatic cytochrome P450 redox potential. *Biochem. Biophys. Res. Commun.* 90, 925-932.
- (49) Lewis, D.F., and Hlavica, P. (2000) Interactions between redox partners in various cytochrome P450 systems: functional and structural aspects. *Biochim. Biophys. Acta.* 1460, 353-374.
- (50) Hlavica, P., Schulze, J., and Lewis, D.F. (2003) Functional interaction of cytochrome P450 with its redox partners: a critical assessment and update of the topology of predicted contact regions. *J. Inorg. Biochem.* 96, 279-297.
- (51) Meunier, B., de Visser, S.P., and Shaik, S. (2004) Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. *Chem. Rev.* 104, 3947-3980.
- (52) Berka, K., Hendrychová, T., Anzenbacher, P., and Otyepka, M. (2011) Membrane position of ibuprofen agrees with suggested access path entrance to cytochrome P450 2C9 active site. *J. Phys. Chem. A.* 115, 11248-11255.

- (53) Lewis, D.F.V., and Hlavica P. (2000) Interactions between redox partners in various cytochrome P450 systems: functional and structural aspects. *Biochim. Biophys. Acta* 1460, 353-374.
- (54) Aono, T., Sakamoto, Y., Miura, M., Takeuchi, F., Hori, H., and Tsubaki, M. (2010) Direct electrochemical analyses of human cytochromes *b*<sub>5</sub> with a mutated heme pocket showed a good correlation between their midpoint and half wave potentials. *J. Biomed. Sci.* 17, 90.
- (55) Im, S.C., and Waskell L. (2011) The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome *b*<sub>5</sub>. *Arch. Biochem. Biophys.* 507, 144-153.
- (56) Iyanagi, T. (1977) Redox properties of microsomal reduced nicotinamide adenine dinucleotide-cytochrome *bs* reductase and cytochrome *b*<sub>5</sub>. *Biochemistry* 16, 2725-2730.
- (57) Yamazaki, H., Johnson, W.W., Ueng, Y.F., Shimada, T., and Guengerich, F.P. (1996) Lack of electron transfer from cytochrome *b*<sub>5</sub> in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome *b*<sub>5</sub>. *J. Biol. Chem.* 271, 27438-27444.

## Legends to Figures

**Figure 1.** Proposed pathways of biotransformation and DNA adduct formation of BaP catalyzed by P450 1A1 and mEH. *Upper*, the typical three-step activation process by P450 1A1 followed by hydrolysis by mEH leads to BPDE which forms dG- $N^2$ -BPDE (adduct 1). *Lower*, the two-step activation process by P450 1A1 leads to the formation of 9-hydroxy-BaP-4,5-epoxide that can react with deoxyguanosine in DNA (adduct 2). *Insert*: Autoradiographic profile of BaP-DNA adducts formed by human P450 1A1 in Supersomes<sup>TM</sup> with mEH in the presence of NADH and cytochrome  $b_5$  as evaluated by TLC  $^{32}$ P-postlabeling as described previously.<sup>19</sup>


**Figure 2.** HPLC analysis of BaP metabolites formed by human recombinant P450 1A1 expressed in Supersomes<sup>TM</sup> in the presence of NADPH (A). Structures of BaP metabolites formed by human P450 1A1 (B). Amounts of BaP metabolites formed by human recombinant P450 1A1 expressed in Supersomes<sup>TM</sup> in the presence of either NADPH or NADH and the effect of cytochrome  $b_5$  (cyt  $b_5$ ) on this metabolism (C). Note that besides human P450 1A1 and POR over-expressed in Supersomes<sup>TM</sup>, this enzymatic system also contained mEH and CBR. Values represent mean  $\pm$  SD from three parallel measurements. \*\*\* $P < 0.001$  (Student's  $t$ -test), significantly different from incubations using NADPH as cofactor;  $\Delta\Delta\Delta P < 0.001$  (Student's  $t$ -test), significantly different from incubations without cytochrome  $b_5$ .

**Figure 3.** BaP metabolism catalyzed by human P450 1A1 reconstituted with POR or CBR with or without cytochrome  $b_5$  (cyt  $b_5$ ). Columns show the sum of individual BaP metabolites formed by P450 1A1 (BaP-3-ol, BaP-9-ol, BaP-1,6-dione, BaP-3,6-dione and the unknown metabolite Mx) Incubations were carried out in the presence of NADPH or NADH.  $\Delta\Delta\Delta P < 0.001$  (Student's  $t$ -test), significantly different from incubations without cytochrome  $b_5$ ; \*\*\* $P < 0.001$  (Student's  $t$ -test), significantly different from incubations with NADPH as cofactor.




**Figure 4.** DNA adduct formation (RAL, relative adduct labelling) by BaP activated with human recombinant P450 1A1 in Supersomes™ in the presence of either NADPH or NADH and the effect of cytochrome *b*<sub>5</sub> (cyt *b*<sub>5</sub>) on this reaction. Note that besides P450 1A1 and POR over-expressed in Supersomes™, this enzymatic system also contained *m*EH and CBR. Values represent mean total RAL ± SD (*n* = 3; analyses of three independent *in vitro* incubations). \*\*\**P* < 0.001 (Student's *t*-test), levels of BaP-adduct 1 significantly different from incubations with NADH but without cytochrome *b*<sub>5</sub>.

**Figure 5.** Autoradiographic profile of BaP-derived DNA adducts generated in DNA by BaP activated with human P450 1A1 in Supersomes™ with *m*EH in the presence of NADH and cytochrome *b*<sub>5</sub> (**A**); with pure human P450 1A1 reconstituted with POR in liposomes in the presence of NADPH (**B**); P450 1A1 with POR in the presence of NADH; P450 1A1 with POR and cytochrome *b*<sub>5</sub> in the presence of NADPH; P450 1A1 with POR and cytochrome *b*<sub>5</sub> in the presence of NADH; P450 1A1 with CBR and cytochrome *b*<sub>5</sub> in the presence of NADPH; P450 1A1 with CBR and cytochrome *b*<sub>5</sub> in the presence of NADH; P450 1A1 with cytochrome *b*<sub>5</sub> in the presence of NADPH; and P450 1A1 with cytochrome *b*<sub>5</sub> in the presence of NADH.


**Figure 6.** The effect of NADPH and/or NADH on BaP-DNA adduct formation (RAL, relative adduct labelling) catalyzed by human recombinant P450 1A1 reconstituted with POR or CBR with or without cytochrome *b*<sub>5</sub> in liposomes. Values are averages ± SD of three independent experiments. \*\*\**P* < 0.001 (Student's *t*-test), levels of BaP-adduct 2 significantly different from incubations with human P450 1A1, POR and NADPH.




**Figure 1**

**A****B****C****Figure 2**






**Figure 3**




**Figure 4**


**A**



**B**



**Figure 5**



**Figure 6**